Hypha Labs, Inc. (FUNI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.28: the stock has moved about 28% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHypha Labs, Inc. (FUNI) trades at $0.0045. Hypha Labs, Inc. focuses on the research, development, and commercialization of the Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human consumption. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for FUNI: FUNI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Hypha Labs, Inc. (FUNI) Healthcare & Pipeline Overview
Hypha Labs, Inc. is a development-stage company focused on the Hypha Micropearl bioreactor, a home appliance designed for accelerated mushroom production. Operating in the medical diagnostics and research industry, the company aims to capitalize on the growing interest in functional foods and home-based health solutions, though it faces significant challenges in commercialization and market adoption.
What Is the Investment Thesis for FUNI?
Hypha Labs, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on the Hypha Micropearl bioreactor targets a niche market within the functional foods and home wellness sectors. However, with a market capitalization of $0.00B and a negative P/E ratio of -1.91, the company's financial viability is uncertain. Key growth catalysts include successful commercialization of the Hypha Micropearl bioreactor and expansion into new markets. The primary risk lies in the company's ability to secure funding, achieve profitability, and compete with established players in the health and wellness industry. Investors should carefully consider the company's limited operating history and the speculative nature of its business model.
Based on FMP financials and quantitative analysis
FUNI Key Highlights
Hypha Labs, Inc. operates in the medical diagnostics and research industry, focusing on home-based bioreactor technology.
- The company's primary product is the Hypha Micropearl bioreactor, designed for accelerated production of beneficial mushrooms.
- Hypha Labs, Inc. has a market capitalization of $0.00B, indicating a micro-cap company with high growth potential but also high risk.
- The company's P/E ratio is -1.91, reflecting current losses and the need for future profitability.
- The company has a beta of 1.28, indicating that the stock is more volatile than the market average.
Who Are FUNI's Competitors?
FUNI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| INBS Intelligent Bio Solutions Inc. | $1.66 | 0.00% | $5.51M | — |
| NDRA ENDRA Life Sciences Inc. | $6.06 | +3.06% | $7.70M | 32 5-pillar |
| ADVB Advanced Biomed Inc. Common Stock | $6.73 | -2.60% | $9.30M | 62 5-pillar |
| BNGO Bionano Genomics, Inc. | $1.48 | -5.73% | $17.0M | — |
| BNR Burning Rock Biotech Limited | $16.25 | +1.63% | $17.2M | — |
| MDXH MDxHealth SA | $0.57 | -0.90% | $29.3M | — |
| QUCY QUCY | $1.34 | -0.74% | $30.5M | — |
| STRR Star Equity Holdings, Inc. | $9.76 | -1.11% | $36.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FUNI's Key Strengths?
Innovative bioreactor technology.
- Focus on a growing market segment.
- Potential for recurring revenue through subscriptions.
What Are FUNI's Weaknesses?
Limited operating history.
- Small team and limited resources.
- Dependence on a single product.
What Are the Key Risks for FUNI?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited financial resources.
- Competition from established players.
- Regulatory hurdles.
- Market acceptance of home-based cultivation.
- Dependence on a single product.
What Are FUNI's Competitive Advantages?
- Proprietary bioreactor technology.
- First-mover advantage in the home-based mushroom cultivation market.
- Potential for brand recognition in the emerging market.
What Does FUNI Do?
Hypha Labs, Inc., incorporated in 2010 and headquartered in Las Vegas, Nevada, is dedicated to the research, development, and commercialization of the Hypha Micropearl bioreactor. This innovative home appliance is designed to accelerate the production of beneficial mushrooms for human consumption. The company's core focus is on providing a convenient solution for individuals seeking to cultivate and consume functional foods at home. The Hypha Micropearl bioreactor represents the company's primary offering, targeting health-conscious consumers interested in incorporating mushrooms with potential health benefits into their diets. Hypha Labs aims to position itself as a leader in the emerging market for home-based bioreactor technology, catering to the growing demand for personalized nutrition and wellness solutions. However, the company is still in its early stages of commercialization and faces the challenge of establishing market acceptance and scaling production. With a small team of 5 employees, Hypha Labs is currently led by A. Stone Douglass. The company's success hinges on its ability to effectively market and distribute the Hypha Micropearl bioreactor, as well as to demonstrate the value proposition of home-based mushroom cultivation to a broad consumer base. The company operates exclusively in the United States.
What Products and Services Does FUNI Offer?
- Researches and develops bioreactor technology.
- Commercializes the Hypha Micropearl bioreactor.
- Offers a home appliance for accelerated mushroom production.
- Targets health-conscious consumers.
- Focuses on functional foods and personalized nutrition.
- Aims to provide a convenient solution for home-based cultivation.
How Does FUNI Make Money?
- Sales of Hypha Micropearl bioreactors to consumers.
- Potential subscription model for spores and nutrients.
- Partnerships with health and wellness companies for distribution.
What Industry Does FUNI Operate In?
Hypha Labs, Inc. operates within the medical diagnostics and research industry, specifically targeting the intersection of functional foods and home-based health solutions. The market for functional foods is experiencing growth, driven by increasing consumer awareness of health and wellness. However, the competitive landscape includes established players in the health appliance and mushroom cultivation sectors. Hypha Labs faces the challenge of differentiating its product and establishing a strong market presence in a rapidly evolving industry. The company's success depends on its ability to capitalize on emerging trends in personalized nutrition and home-based health technologies.
Who Are FUNI's Key Customers?
- Health-conscious consumers.
- Individuals interested in functional foods.
- People seeking home-based health solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Hypha Labs, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO A. Stone Douglass. FUNI has traded publicly since 2012.
Key Financial Metrics
Return on equity for Hypha Labs, Inc. stands at 73.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -81.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Hypha Labs, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FUNI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
FUNI Latest News
No recent news available for FUNI.
FUNI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FUNI.
Price Targets
Wall Street price target analysis for FUNI.
FUNI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FUNI; grades run from A+ (80-100) to F (below 30).
Leadership: A. Stone Douglass
CEO
A. Stone Douglass is the CEO of Hypha Labs, Inc., managing a small team of 5 employees. Information regarding A. Therefore, a comprehensive background cannot be provided.
Track Record: Due to limited information, A. Stone Douglass's key achievements, strategic decisions, and company milestones under their leadership cannot be accurately assessed. Further data is needed to evaluate their track record at Hypha Labs, Inc.
FUNI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hypha Labs, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should be aware of the increased risks associated with investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited liquidity and trading volume.
- Less stringent regulatory oversight.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any legal or regulatory actions against the company.
- Company incorporation in 2010 suggests some operational history.
- Focus on a specific product (Hypha Micropearl bioreactor) indicates a defined business strategy.
- Presence of a CEO (A. Stone Douglass) suggests leadership structure.
FUNI Healthcare Stock FAQ
What are the main risks for FUNI?
The main risks for Hypha Labs, Inc. include its limited operating history, small team and resources, and dependence on a single product.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available for Hypha Labs, Inc.
- OTC market investments carry higher risk.